Authorised Therapeutic exploratory (Phase II) Severe burns

Evolution of the initial distribution volume of glucose in the severe burned adults

EU CTIS ID: 2024-513874-23-00

What this study is testing

Description of the mean values of the initial volume of glucose distribution (IDVG) during the first four days of management of a severely burned patient.

  • Therapeutic exploratory (Phase II)

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Who can take part

You may be able to join if

  • Patients over 18 years of age
  • Patients hospitalized with burns of at least 30% of body surface area o By a thermal mechanism o At the CHR Metz-Thionville burn center o managed within the 8 hours post-burn
  • Patient affiliated to a social security scheme
  • Written consent obtained from the patient (or from the trusted person, family or relatives if the patient is unable to sign/express consent) or emergency inclusion if the patient is unable to express consent and neither the trusted support person nor any member of the family or relatives is present at the time of inclusion

You likely can't join if

  • Diabetic patients on insulin
  • Cognitive impairment or language barrier
  • Patient with a CONTRAINDICATION to GLUCOSE 30% PROAMP, solution for injection
  • Patients with pre-hospital cardiac arrest
  • Patient with extra corporeal circulation : Extra Corporeal Membranous Oxygenation (ECMO) or Extra Corporeal Life Support (ECLS) or CRRT (Continuous Renal Replacement Therapy)
  • Patient without central venous line or arterial catheter
See the full eligibility criteria
Who can join
  • Patients over 18 years of age
  • Patients hospitalized with burns of at least 30% of body surface area o By a thermal mechanism o At the CHR Metz-Thionville burn center o managed within the 8 hours post-burn
  • Patient affiliated to a social security scheme
  • Written consent obtained from the patient (or from the trusted person, family or relatives if the patient is unable to sign/express consent) or emergency inclusion if the patient is unable to express consent and neither the trusted support person nor any member of the family or relatives is present at the time of inclusion
What rules you out
  • Diabetic patients on insulin
  • Cognitive impairment or language barrier
  • Patient with a CONTRAINDICATION to GLUCOSE 30% PROAMP, solution for injection
  • Patients with pre-hospital cardiac arrest
  • Patient with extra corporeal circulation : Extra Corporeal Membranous Oxygenation (ECMO) or Extra Corporeal Life Support (ECLS) or CRRT (Continuous Renal Replacement Therapy)
  • Patient without central venous line or arterial catheter
  • Patient moribund or immediately subject to therapeutic limitation
  • Impossibility of trans-pulmonary thermodilution monitoring (vascular access difficulties)
  • Pregnant, parturient or breast-feeding women
  • Patient under guardianship, curatorship or safeguard of justice

The study team makes the final eligibility decision.

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.